Oxnard, CA, December 2017 – FOMAT Medical Research, a leading organization in clinical research, is launching a joint venture with Reumalab in order to provide clinical research services in Medellin, Colombia, that is set to improve clinical research outcomes in Latin America.
FOMAT Medical Research will provide clinical, administrative, and regulatory management while Reumalab will address operations in the new joint venture. FOMAT Medical Research is well-known in the drug development industry for managing and operating high-quality clinical research in the U.S. and Latin America. Reumalab, a well-respected and established organization in rheumatology and other therapeutic areas will bring their experience in clinical research and high-quality facilities to the joint venture with FOMAT and will continue to set high standards and lead clinical research in Colombia.
About FOMAT Medical Research
Is an international company focused on innovating healthcare for minorities throughout the Americas by pushing for the representation of minorities in clinical research data in the U.S., FOMAT is a Site Network Organization (SNO) with leading sites in an array of therapeutic areas. In Latin America, FOMAT assists in clinical research as an SNO with local CRO capabilities, which means that FOMAT can play both roles, especially in Ecuador, Colombia, and Peru. This added benefit allows FOMAT to have the fastest start-up times both quickly and efficiently.
In 1969, Javier Molina, M.D., pioneered the implementation of new techniques for the diagnosis of rheumatic diseases and created rheumatology services in the “Hospital San Vicente de Paul” and the Social Security Institute. In the same year, Dr. Molina founded the Specialized Clinical Laboratory in Rheumatology, as support to process the samples of his patients to make more precise diagnoses. Since then, the laboratory has been the standard bearer in the performance of different rheumatologic tests such as antinuclear antibodies, rheumatoid factors, synovial fluid studies, anticardiolipin antibodies, biochemical markers for osteoporosis, among others. Subsequently, his private practice and the clinical laboratory were transformed into the Reumalab Integral Rheumatology Center in which the best diagnostic practices were combined with care for patients with different pathologies; and in 1997, in conjunction with Dr. Jose Fernando Molina, specialized research in patients with rheumatologic and autoimmune diseases. Today, Reumalab continues to expand in other therapeutic areas and is a top and leading clinical research center in Medellin, Colombia.